Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Tapinarof cream 1% for corticosteroid-refractory erythema annulare centrifugum: A first reported case.

JAAD case reports·2026

Same author

Modestly Increased Incidence of Irritable Bowel Syndrome in Hidradenitis Suppurativa: A Retrospective Cohort Study Using TriNetX.

International journal of dermatology·2026

Same author

Response to Choi et al, "Pathergy beyond neutrophilic dermatoses: A case of localized leukemia cutis at the site of intravenous infiltration".

JAAD case reports·2026

Same author

A linear purpuric rash in an elderly man.

JAAD case reports·2025

Same author

Carcinoma erysipeloides secondary to male breast cancer in a patient with BRCA1 and BRCA2 mutations: a clinical presentation and management.

BMJ case reports·2025

Same author

Disparities and longitudinal complications in opioid prescriptions after dermatologic surgery: An international propensity score-matched, retrospective cohort study.

International journal of dermatology·2024

Search research articles

Related Experiment Video

Updated: Sep 11, 2025

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Refractory cutaneous pseudolymphoma treated with tapinarof.

Shravya Kichena¹, Emily Limmer², Dario Kivelevitch^2,3,4

¹Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center, El Paso, Texas, USA.

Proceedings (Baylor University. Medical Center)

|August 18, 2025

Summary

This case study explores tapinarof cream for treating cutaneous pseudolymphoma (CPL), a condition mimicking lymphoma. Tapinarof showed promising results in a patient with refractory CPL, suggesting its potential as a novel therapeutic option.

Keywords:

Aryl hydrocarbon receptor cutaneous pseudolymphoma lymphoproliferative disorders tapinarof

More Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

Related Experiment Videos

Last Updated: Sep 11, 2025

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

Area of Science:

Dermatology
Oncology

Background:

Cutaneous pseudolymphoma (CPL) is a benign lymphoproliferative disorder that mimics cutaneous lymphoma.
Accurate diagnosis and effective treatment can be challenging due to its variable presentation.

Observation:

A 62-year-old woman presented with a persistent erythematous plaque and papules on her nose, initially diagnosed as pseudolymphoma.
Previous treatments with mometasone and tacrolimus were ineffective.

Findings:

Treatment with tapinarof cream 1% resulted in significant clinical improvement over 10 months, with reduced plaque and papules and only mild residual erythema.
This suggests tapinarof may be effective for refractory CPL.

Implications:

Tapinarof cream demonstrates potential as a safe and effective treatment for refractory cutaneous pseudolymphoma.
Further research is warranted to establish tapinarof's role in managing CPL and similar inflammatory skin conditions.